Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ULORIC

« Back to Dashboard
Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from four suppliers. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has eigthy-seven patent family members in thirty-four countries.

The generic ingredient in ULORIC is febuxostat. There are nineteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the febuxostat profile page.

Summary for Tradename: ULORIC

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list12

Pharmacology for Tradename: ULORIC

Clinical Trials for: ULORIC

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Status: Completed Condition: Gout

The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
Status: Terminated Condition: Blood Pressure; Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Status: Recruiting Condition: Gout

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Status: Completed Condition: Chronic Kidney Disease; Diabetes

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Status: Completed Condition: Renal Impairment

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
Status: Recruiting Condition: Gout; Moderate Renal Impairment

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
Status: Completed Condition: Gout; Hyperuricemia

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Status: Completed Condition: Gout

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
Status: Completed Condition: Gout

Efficacy and Safety of Oral Febuxostat in Participants With Gout
Status: Completed Condition: Gout

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXNo5,614,520<disabled>YY<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYes6,225,474<disabled>Y<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXNo6,225,474<disabled>Y<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYes7,361,676<disabled>Y<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXNo8,372,872<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ULORIC

Drugname Dosage Strength RLD Submissiondate
febuxostatTablets40 mg and 80 mgUloric2/13/2013

International Patent Family for Tradename: ULORIC

Country Document Number Publication Date
China1275126Nov 29, 2000
World Intellectual Property Organization (WIPO)9965885Dec 23, 1999
Denmark1956015Sep 26, 2011
CroatiaP20120217May 31, 2012
Slovakia287946Jun 04, 2012
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc